Looking at the filing, I can confirm this is a 10-Q for Treace Medical Concepts, Inc., trading as NASDAQ:TMCI, for the quarterly period ended September 30, 2026. The filing content provided is primarily the cover page, table of contents, and forward-looking statements section. I need to extract the substantive disclosure content. The forward-looking statements section contains over 150 words of substantive content about the company's business, products, and risk factors, so I will proceed with the article.

Treace Medical Concepts, Inc. (NASDAQ:TMCI) filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 6, 2026, disclosing operational and financial information for the three months ended on that date.

Key Highlights

  • Shares outstanding: As of October 30, 2026, the company reported 65,559,597 shares of common stock, $0.001 par value per share, outstanding.
  • Filer status: The company is classified as an accelerated filer, and not a smaller reporting company or emerging growth company, according to the filing.
  • Flagship product: The filing identifies the Lapiplasty system as the company's flagship product, noting it carries higher average selling prices than the company's newer osteotomy and great toe fusion systems.
  • Intellectual property actions: The filing references lawsuits the company initiated in October 2024 and May 2025 related to unauthorized use and infringement of its intellectual property.
  • Market focus: The company disclosed it operates in the foot and ankle market, with products used in bunion surgeries across both the Lapidus market and the minimally invasive osteotomy market.
  • Care setting shift: The filing notes a shift in elective bunion surgeries from hospitals to ambulatory surgery centers as a factor the company is monitoring and responding to.

Treace Medical Concepts Reports on Q3 2026 Operations and Product Portfolio

Treace Medical Concepts, Inc., a Delaware-incorporated medical device company headquartered at 100 Palmetto Park Place, Ponte Vedra, Florida 32081, submitted its quarterly report covering the period ended September 30, 2026. The company's common stock is listed on The Nasdaq Global Select Market under the ticker TMCI, according to the filing's registered-securities table. The report was filed under Commission file number 001-40355.

According to the filing, the company's commercial focus centers on bunion surgery solutions, including its flagship Lapiplasty system, which the company disclosed commands higher average selling prices relative to its newer osteotomy and great toe fusion product lines. The filing describes the company's market environment as including competition from both the Lapidus market and the minimally invasive osteotomy market, with the company citing new product introductions from other industry participants as an ongoing competitive consideration. The filing also highlights evolving surgeon and patient preferences for bunion surgery treatments as a factor shaping demand.

The company disclosed several operational and macroeconomic factors it is monitoring, including the impact of "softening consumer sentiment, higher insurance deductibles and costs, higher energy prices, persistent inflationary pressures, interest rate changes," evolving tariffs, and geopolitical tensions on patient demand for elective surgeries and on its broader business results. The filing also references the company's efforts to expand active surgeon counts and maintain case volumes, as well as its stated goal of leveraging its commercial infrastructure to support demand and improve profitability. The forward-looking statements contained in the filing are the company's own and are subject to the cautionary language described within the document.

What Was Disclosed

Treace Medical Concepts filed a quarterly report for the period ended September 30, 2026, disclosing 65,559,597 shares outstanding as of October 30, 2026, its accelerated filer classification, its flagship Lapiplasty system, ongoing intellectual property litigation, and a range of market and macroeconomic risk factors affecting its foot and ankle surgery business.